Ashley Keating - Medpace Holdings Director
| MEDP Stock | USD 395.93 6.16 1.58% |
Director
Ms. Ashley M. Keating is Director of the Company. Ms. Keating is currently the Chief Financial Officer of CincyTech, one of the most active seedstage investors in the Midwest focused on providing startup capital and guidance to human health and technology companies primarily in Southwest Ohio. From 2005 to April 2016, Ms. Keating worked at PricewaterhouseCoopers where she focused on finance, operations, business leadership and mergers and acquisitions. She began her career in audit services at PwCs Cincinnati office and later transferred to PwCs transaction services practice in the New York and London offices since 2019.
| Tenure | 5 years |
| Address | 5375 Medpace Way, Cincinnati, OH, United States, 45227 |
| Phone | 513 579 9911 |
| Web | https://www.medpace.com |
Ashley Keating Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ashley Keating against Medpace Holdings stock is an integral part of due diligence when investing in Medpace Holdings. Ashley Keating insider activity provides valuable insight into whether Medpace Holdings is net buyers or sellers over its current business cycle. Note, Medpace Holdings insiders must abide by specific rules, including filing SEC forms every time they buy or sell Medpace Holdings'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ashley Keating over a month ago Disposition of 250 shares by Ashley Keating of Medpace Holdings at 409.87 subject to Rule 16b-3 |
Medpace Holdings Management Efficiency
The company has return on total asset (ROA) of 0.1389 % which means that it generated a profit of $0.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6135 %, meaning that it created $0.6135 on every $100 dollars invested by stockholders. Medpace Holdings' management efficiency ratios could be used to measure how well Medpace Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Medpace Holdings' Return On Capital Employed is relatively stable compared to the past year. As of 04/28/2024, Return On Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop 0.16. At this time, Medpace Holdings' Total Current Liabilities is relatively stable compared to the past year. As of 04/28/2024, Non Current Liabilities Total is likely to grow to about 182.2 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.3 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gary Hendrickson | Waters | 64 | |
| Elisha Finney | Mettler Toledo International | 59 | |
| Gary Gilliland | Laboratory of | 63 | |
| Kerrii Anderson | Laboratory of | 63 | |
| Richard Crowder | Neogen | 56 | |
| James Tobin | Neogen | 61 | |
| Bruce Papesh | Neogen | 70 | |
| Bryan Brokmeier | Waters | N/A | |
| Anne Szostak | IDEXX Laboratories | 67 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Lawrence Kingsley | IDEXX Laboratories | 55 | |
| Frederick Craves | Twist Bioscience Corp | 72 | |
| Bruce Claflin | IDEXX Laboratories | 66 | |
| Keith Crandell | Twist Bioscience Corp | 58 | |
| Sam Samad | IDEXX Laboratories | 48 | |
| Sophie Vandebroek | IDEXX Laboratories | 56 | |
| Clayton Yeutter | Neogen | 85 | |
| Robert Ragusa | Twist Bioscience Corp | 58 | |
| Xiaoying Mai | Twist Bioscience Corp | 30 | |
| WahHui Chu | Mettler Toledo International | 69 | |
| William Boehm | Neogen | 70 | |
Management Performance
| Return On Equity | 0.61 | ||||
| Return On Asset | 0.14 |
Medpace Holdings Leadership Team
Elected by the shareholders, the Medpace Holdings' board of directors comprises two types of representatives: Medpace Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medpace. The board's role is to monitor Medpace Holdings' management team and ensure that shareholders' interests are well served. Medpace Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medpace Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Burwig, Senior Vice President - Operations | ||
| Cornelius McCarthy, Director | ||
| Anastasya Molodykh, Director | ||
| Kevin Brady, CFO Treasurer | ||
| Jesse Geiger, CFO, COO - Laboratory Operations | ||
| Stephen JD, General Officer | ||
| Stephen Ewald, General Counsel, Corporate Secretary | ||
| Bruce Brown, Independent Director | ||
| Matthew Norton, Independent Director | ||
| John MBA, Senior Unit | ||
| MA BSN, Executive Operations | ||
| Ashley Keating, Director | ||
| John Richardson, Director | ||
| Fred Davenport, Director | ||
| August Troendle, Chairman of the Board and Presidentident, CEO | ||
| Alexander Leslie, Independent Director | ||
| Brandon Ebken, Chief Officer | ||
| August MD, Chairman CEO | ||
| Todd Meyers, Vice Marketing | ||
| Reinilde MD, Chief Department | ||
| Weimin MS, VP Biometrics | ||
| Supraj Rajagopalan, Independent Director | ||
| Penelope Bucknell, Vice President - Human Resources | ||
| Daniel OLeary, VP Department | ||
| Brian Carley, Independent Director | ||
| Robert Kraft, Independent Director | ||
| CPA BBA, President | ||
| Lauren Morris, Associate Relations |
Medpace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medpace Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.61 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 11.99 B | ||||
| Shares Outstanding | 30.98 M | ||||
| Shares Owned By Insiders | 18.16 % | ||||
| Shares Owned By Institutions | 81.68 % | ||||
| Number Of Shares Shorted | 984.45 K | ||||
| Price To Earning | 49.07 X |
Medpace Holdings Investors Sentiment
The influence of Medpace Holdings' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Medpace. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Medpace Holdings' public news can be used to forecast risks associated with an investment in Medpace. The trend in average sentiment can be used to explain how an investor holding Medpace can time the market purely based on public headlines and social activities around Medpace Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Medpace Holdings' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Medpace Holdings' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Medpace Holdings' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Medpace Holdings.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Medpace Holdings in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Medpace Holdings' short interest history, or implied volatility extrapolated from Medpace Holdings options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medpace Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Medpace Stock, please use our How to Invest in Medpace Holdings guide.Note that the Medpace Holdings information on this page should be used as a complementary analysis to other Medpace Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Medpace Stock analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Medpace Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medpace Holdings. If investors know Medpace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medpace Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.41 | Earnings Share 9.82 | Revenue Per Share 63.975 | Quarterly Revenue Growth 0.177 | Return On Assets 0.1389 |
The market value of Medpace Holdings is measured differently than its book value, which is the value of Medpace that is recorded on the company's balance sheet. Investors also form their own opinion of Medpace Holdings' value that differs from its market value or its book value, called intrinsic value, which is Medpace Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medpace Holdings' market value can be influenced by many factors that don't directly affect Medpace Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medpace Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medpace Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medpace Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.